NVG-291 for Spinal Cord Injury

(RESTORE Trial)

This trial tests a new treatment called NVG-291, an experimental therapy, to determine if it can improve hand function and daily activities in individuals with a spinal cord injury in the neck area. Researchers aim to assess the safety and effectiveness of this treatment compared to a placebo, which resembles the treatment but lacks the active ingredient. Participants will receive daily injections for 12 weeks and attend regular checkups. The trial suits adults who experienced a cervical spinal cord injury 1 to 10 years ago and still retain some movement in their arms or legs. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

In a previous study, patients generally tolerated NVG-291 well, meaning most did not experience serious side effects. Common side effects included mild headaches and slight nausea, typical for many medications and not severe enough to halt treatment. Since this trial is in a late stage, NVG-291 has already undergone earlier testing and demonstrated sufficient safety for broader testing. This is encouraging for potential participants, as it indicates NVG-291 has been safe for human use so far.¹²³⁴⁵

Unlike the standard treatments for spinal cord injury, which often focus on rehabilitation and managing symptoms, NVG-291 is unique because it targets a specific pathway in the body to promote nerve repair. This new mechanism of action is designed to enhance the body's natural ability to heal by modulating a protein involved in nerve growth and repair. Researchers are excited about NVG-291 because it offers a novel approach that could potentially improve recovery outcomes for patients with spinal cord injuries, providing hope for more effective healing.

Research has shown that NVG-291, which participants in this trial may receive, may help people with long-term spinal cord injuries improve their abilities. In various studies, this treatment led to noticeable improvements in movement, self-care, and quality of life. For instance, patients using NVG-291 gained better control over their arms and legs and became more active daily. It also calmed overactive nerve signals, which is important for improved movement. Overall, NVG-291 has shown potential in helping patients regain some lost abilities.⁶⁷⁸⁹¹⁰